Elevated pre-surgical CA15-3: does it predict the short-term disease-free survival of breast cancer patients without distant metastasis?

Mudduwa, Lakmini; Wijayaratne, Weerasinghe Mudiyanselage Dilip Gaya Bandara; Peiris, Harshini; Gunasekera, Shania N; Abeysiriwardhana, Deepthika; Liyanage, N. D. L.

doi:10.2147/ijwh.s162867

Cited by 11 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They reported that patients with [CA15-3] (≤30 U/mL) had better DFS than patients with CA15-3 (≥30 U/mL). Moreover, they demonstrated that CA15-3 was positively correlated with the initial tumor size (27). Incoronato et al studied the association between CA15-3 and PET/CT (hybrid positron emission tomography and computed tomography) findings.…”

mentioning

confidence: 99%

Correlation of cancer antigen 15-3 (CA15-3) serum level and bony metastases in breast cancer patients

Fakhari

Gharepapagh

Oskuei

et al. 2019

Med. J. Islam. Republ. Iran

View full text Add to dashboard Cite

Background: Cancer antigen 15-3 (CA15-3) is a common tumor marker and the serum level of this tumor marker is evaluated during the treatment period (periodically) in breast cancer patients. Assuming that the elevated serum levels of this tumor marker can be a potential risk, this study was conducted to determine the association between CA15-3 and bone metastasis and CA15-3 and metastasis spreading rate in breast cancer patients. Methods: In this study, 70 women with the mean of age 51.69 (10.77) years who suffered from breast cancer were studied by performing both bone scintigraphy and measuring CA15-3. Independent sample t test, Fisher's exact test, Spearman rho correlation, and logistic regression were used for inferential section. To determine the new cross section, Roc curve and coordinates of the curve were applied. Also, significance level was set at p<0.05. Data were analyzed by SPSS 16 software. Results: There was no difference among patients in age (p=0.123). Assuming the CA15-3 (≥ 30 U/mL) as a potential risk, there was no association between CA15-3 and bone metastases (p=0.167). Based on Spearman's rank correlation coefficient, there was no significant correlation between CA15-3 and metastasis spreading rate (r=-0.07, p=0.851). Based on ROC curve and Youden's J statistic index, the new cutoff was pointed at CA15-3 ≥21.76 Unit/mL, which correlated with bone metastases (p<0.001). Conclusion: This study found a decreased cutoff point at CA15-3 (≥21.76) against 30 (routine value). Based on CA15-3 (≥21.76), there was a correlation between bone metastases and CA15-3, indicating that patients with CA15-3 (≥21.76) were most likely to experience bone metastases.

show abstract

mentioning

confidence: 99%

Correlation of cancer antigen 15-3 (CA15-3) serum level and bony metastases in breast cancer patients

Fakhari

Gharepapagh

Oskuei

et al. 2019

Med. J. Islam. Republ. Iran

View full text Add to dashboard Cite

show abstract

“…Patients having greater size of tumor (p < 0:0001) along with nodal metastasis (p = 0:0001) revealed higher rates of elevated CA15-3 levels, similar to our results. Mudduwa1 et al [21] identified a significant association only between elevated preoperative CA15-3 and tumor size. However, overexpression of ER, PR, and HER2 did not exhibit a significant correlation with preoperative CA15-3 levels.…”

Section: Discussionmentioning

confidence: 98%

Evaluation of Preoperative CA15-3 Level and its Relationship with Clinico-Pathological Characteristics in Primary Breast Cancer Patients

Hameed,

Al-Rayahi,

Muhsin

2022

View full text Add to dashboard Cite

Cancer antigen15-3 (CA15-3) is utilized as a tumor marker in breast cancer. In the metastatic situation, it has been regarded as having a predictive role. However, the usefulness of serum CA15-3 in preoperative breast cancer remains argumentative. Therefore, this study aimed to estimate the association of preoperative serum CA15-3 level with the clinico-pathological characteristics in Iraqi women patients with breast tumor and their efficiency for the prediction of primary breast cancer. Preoperative CA15-3 levels were assessed by ELISA technique in 60 Iraqi women with breast tumor (30 with primary breast cancer and 30 with benign breast tumor) before surgery and treatment, as well as 30 healthy controls. In addition, the clinico-pathological characteristics information of all the patients was reported. CA15-3 level showed a significant difference between its level in the sera of primary breast cancer women in comparison to the benign breast tumor women (p <0.001) and healthy control women one (p <0.001). The area under the curve (AUC) of CA15-3 for discriminating patients with primary breast cancer and healthy control subjects was 0.720 (95% CI: 0.589 to 0.828). Furthermore, the present study showed that higher preoperative CA15-3 level was significantly associated with a larger tumor size and lymph node metastasis. This means that elevated CA15-3 is correlated with an increased tumor burden, suggesting its predictive value.

show abstract

“…CA15-3 is currently recommend for use in monitoring metastatic potential in active treatment, assessing prognosis, and early detection of disease progression [73]. Elevated levels of CA15-3 are correlated with poor clinical outcomes and both disease-free and overall survival [73,74]. Development of an aptamer for this target is not critical, as multiple commercial tests are available and in use.…”

Section: Carbohydrate/cancer Antigen 15-3 (Ca 15-3)mentioning

confidence: 99%

Breast Cancer Aptamers: Current Sensing Targets, Available Aptamers, and Their Evaluation for Clinical Use in Diagnostics

Varty

O’Brien

Ignaszak

2021

Cancers

View full text Add to dashboard Cite

Breast cancer is the most commonly occurring cancer in women worldwide, and the rate of diagnosis continues to increase. Early detection and targeted treatment towards histological type is crucial to improving outcomes, but current screening methods leave some patients at risk of late diagnosis. The risk of late diagnosis and progressed disease is of particular concern for young women as current screening methods are not recommended early in life. Aptamers are oligonucleotides that can bind with high specificity to target molecules such as proteins, peptides, and other small molecules. They are relatively cheap to produce and are invariable from batch to batch, making them ideal for use in large-scale clinical or screening programs. The use of aptamers for breast cancer screening, diagnosis, and therapeutics is promising, but comparison of these aptamers and their corresponding biomarkers for use in breast cancer is significantly lacking. Here, we compare the currently available aptamers for breast cancer biomarkers and their respective biomarkers, as well as highlight the electrochemical sensors that are in development.

show abstract

Elevated pre-surgical CA15-3: does it predict the short-term disease-free survival of breast cancer patients without distant metastasis?

Cited by 11 publications

References 19 publications

Correlation of cancer antigen 15-3 (CA15-3) serum level and bony metastases in breast cancer patients

Correlation of cancer antigen 15-3 (CA15-3) serum level and bony metastases in breast cancer patients

Evaluation of Preoperative CA15-3 Level and its Relationship with Clinico-Pathological Characteristics in Primary Breast Cancer Patients

Breast Cancer Aptamers: Current Sensing Targets, Available Aptamers, and Their Evaluation for Clinical Use in Diagnostics

Contact Info

Product

Resources

About